Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Advisory Panels Off To Slow Start In 2007 After Role Change In 2006

Executive Summary

FDA is on pace to hold fewer advisory committee meetings in 2007 than in 2006

You may also be interested in...

Genasense Accelerated Approval Not Supported Due To Failed Outcomes Data

Accelerated approval based on response rate is not appropriate for Genta's Genasense given the Bcl-2 inhibitor's failure to show a benefit on clinical outcomes in a randomized Phase III trial, FDA and members of its Oncologic Drugs Advisory Committee said during a Sept. 6 meeting

FDA Accepts Progression Endpoint For Gemzar Ovarian Cancer Indication

FDA's approval of Lilly's Gemzar to treat ovarian cancer - contrary to the advice of its Oncologic Drugs Advisory Committee - demonstrates the agency's willingness to accept progression-free survival as a clinically meaningful endpoint

Cellegesic Draws Split Vote On Need For New Study On Anal Fissure Pain

Cellegy's Cellegesic for anal fissures may or may not need a new study for approval following a split decision by FDA's Cardiovascular and Renal Drugs Advisory Committee at its April 25 meeting

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts